Rain Enhancement Technologies Holdco (RAIN)
Market Price (11/4/2026): $0.521 | Market Cap: $6.1 MilSector: Industrials | Industry: Environmental & Facilities Services
Rain Enhancement Technologies Holdco (RAIN)
Market Price (11/4/2026): $0.521Market Cap: $6.1 MilSector: IndustrialsIndustry: Environmental & Facilities Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78% Megatrend and thematic driversMegatrends include Climate Adaptation & Resilience. Themes include Atmospheric Water Management, and Water Security Solutions. | Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -175% | Penny stockMkt Price is 0.5 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -101874% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 204% Expensive valuation multiplesP/SPrice/Sales ratio is 417x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 31721% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -32967%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -36629% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -273% High stock price volatilityVol 12M is 138% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78% |
| Megatrend and thematic driversMegatrends include Climate Adaptation & Resilience. Themes include Atmospheric Water Management, and Water Security Solutions. |
| Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -175% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -101874% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 204% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 417x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 31721% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -32967%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -36629% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -273% |
| High stock price volatilityVol 12M is 138% |
Qualitative Assessment
AI Analysis | Feedback
Rain Enhancement Technologies Holdco (RAIN) stock has lost about 60% since 7/31/2026 because of the following key factors:
1. Continued Lack of Revenue and Significant Losses. Rain Enhancement Technologies Holdco consistently reported zero revenue for multiple fiscal quarters, including fiscal Q2 2026, which ended on June 30, 2026. This period also saw significant net losses, totaling -$11.8 million for the trailing twelve months ending in fiscal Q2 2026, with a net income loss of -$3.2 million for Q2 2026 alone.
2. Severe Liquidity Concerns and Going Concern Doubts. As of October 3, 2026, the company exhibited critical financial instability with a current ratio of merely 0.03 and negative total equity of -$12,157,084. These severe liquidity issues have raised substantial doubt about the company's ability to continue as a going concern, significantly eroding investor confidence.
Show more
Rain Enhancement Technologies Holdco (RAIN) stock has lost about 60% since 7/31/2026 because of the following key factors:
1. Continued Lack of Revenue and Significant Losses. Rain Enhancement Technologies Holdco consistently reported zero revenue for multiple fiscal quarters, including fiscal Q2 2026, which ended on June 30, 2026. This period also saw significant net losses, totaling -$11.8 million for the trailing twelve months ending in fiscal Q2 2026, with a net income loss of -$3.2 million for Q2 2026 alone.
2. Severe Liquidity Concerns and Going Concern Doubts. As of October 3, 2026, the company exhibited critical financial instability with a current ratio of merely 0.03 and negative total equity of -$12,157,084. These severe liquidity issues have raised substantial doubt about the company's ability to continue as a going concern, significantly eroding investor confidence.
3. Strategic Business Combination Indicating Distress. On September 23, 2026, Rain Enhancement Technologies Holdco announced a Binding Letter of Intent for a strategic business combination with Tensor Networks, with Tensor set to take approximately a 90% stake in Rain Enhancement Technologies. This highly dilutive event for existing shareholders was likely perceived as a distress-driven acquisition, contributing to the stock's steep decline.
4. Macroeconomic Headwinds for Pre-Revenue Companies. The broader market environment during fiscal Q3 2026 (ended September 30, 2026) presented significant macroeconomic pressure, particularly for speculative and pre-revenue companies. The Federal Reserve raised the federal funds rate on September 16, 2026, to 3.75–4.00%, with the 10-year Treasury yield climbing to about 5.3%. This higher interest rate environment disproportionately impacted "long-duration assets" and small-cap pre-revenue companies, contributing to a more than 7% drop in the Russell 2000 during the quarter.
Show less
Stock Movement Drivers
Fundamental Drivers
The -62.3% change in RAIN stock from 7/31/2026 to 11/2/2026 was primarily driven by a -61.2% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11022026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.44 | 0.54 | -62.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 1,081.7 | 419.5 | -61.2% |
| Shares Outstanding (Mil) | 8 | 8 | -2.8% |
| Cumulative Contribution | -62.3% |
Market Drivers
7/31/2026 to 11/2/2026| Return | Correlation | |
|---|---|---|
| RAIN | -62.3% | |
| Market (SPY) | 0.7% | -3.1% |
| Sector (XLI) | -5.6% | -0.9% |
Fundamental Drivers
The -74.0% change in RAIN stock from 4/30/2026 to 11/2/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11022026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.09 | 0.54 | -74.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 419.5 | |
| Shares Outstanding (Mil) | 8 | 8 | -6.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 11/2/2026| Return | Correlation | |
|---|---|---|
| RAIN | -74.0% | |
| Market (SPY) | 4.9% | 9.6% |
| Sector (XLI) | -2.6% | 2.0% |
Fundamental Drivers
The -89.7% change in RAIN stock from 10/31/2025 to 11/2/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11022026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.26 | 0.54 | -89.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 419.5 | |
| Shares Outstanding (Mil) | 7 | 8 | -15.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 11/2/2026| Return | Correlation | |
|---|---|---|
| RAIN | -89.7% | |
| Market (SPY) | 11.2% | 9.4% |
| Sector (XLI) | 10.4% | 2.7% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/2/2026| Return | Correlation | |
|---|---|---|
| RAIN | ||
| Market (SPY) | 86.0% | 6.4% |
| Sector (XLI) | 79.4% | 4.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RAIN Return | - | - | - | - | -20% | -91% | -93% |
| Peers Return | 37% | -15% | 22% | 11% | 9% | -3% | 66% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| RAIN Win Rate | - | - | - | - | 50% | 27% | |
| Peers Win Rate | 65% | 42% | 55% | 55% | 63% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| RAIN Max Drawdown | - | - | - | - | - | -91% | |
| Peers Max Drawdown | -17% | -36% | -21% | -18% | -26% | -34% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XYL, PNR, WTS, TTEK, LNN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/2/2026 (YTD)
How Low Can It Go
| Event | RAIN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.2% | -18.8% |
| % Gain to Breakeven | 41.2% | 23.1% |
| Time to Breakeven | 32 days | 79 days |
In The Past
Rain Enhancement Technologies Holdco's stock fell -29.2% during the 2025 US Tariff Shock. Such a loss loss requires a 41.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RAIN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.2% | -18.8% |
| % Gain to Breakeven | 41.2% | 23.1% |
| Time to Breakeven | 32 days | 79 days |
In The Past
Rain Enhancement Technologies Holdco's stock fell -29.2% during the 2025 US Tariff Shock. Such a loss loss requires a 41.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Rain Enhancement Technologies Holdco (RAIN)
RAIN operates as a clinical-stage precision oncology company focused on developing innovative therapies to target oncogenic drivers, which are genes that contribute to cancer development. The company's mission is to address significant unmet medical needs in cancer treatment through a targeted approach.
Its primary product candidate is milademetan, a small molecule oral inhibitor designed to block mouse double minute 2 (MDM2), a protein often overactive in various cancers. Milademetan is currently undergoing a Phase 3 clinical trial for liposarcoma, as well as Phase II clinical trials for solid tumors and intimal sarcoma, representing its most advanced therapeutic efforts.
In addition to milademetan, RAIN is also advancing RAD52, another promising candidate in preclinical trials for a range of cancers including breast, ovarian, pancreatic, and prostate. The company primarily serves the oncology market within the United States, aiming to provide precision treatments for patients battling these life-threatening diseases.
AI Analysis | Feedback
It's like an early-stage **Gilead Sciences** or **Vertex Pharmaceuticals**, but solely focused on developing new cancer therapies.
Think of it as a specialized **Amgen** or **Roche** that is still in the process of bringing its first major cancer drugs to market through clinical trials.
AI Analysis | Feedback
- Milademetan: A small molecule oral inhibitor of mouse double minute 2 (MDM2) that is being developed for various cancers, including liposarcoma, solid tumors, and intimal sarcoma.
- RAD52: A preclinical-stage drug candidate being investigated for its potential in treating a range of tumors, such as breast, ovarian, pancreatic, and prostate cancers.
AI Analysis | Feedback
Based on the provided background description, Rain Therapeutics Inc. (symbol: RAIN) is a clinical-stage precision oncology company. Its primary focus is on the development of therapies that target oncogenic drivers, such as milademetan and RAD52, which are currently in various phases of clinical trials (Phase 3, Phase II, and preclinical stages).
As a company in the clinical development stage, Rain Therapeutics Inc. does not currently have major customers in the traditional sense, as its product candidates have not yet received regulatory approval for commercial sale. Therefore, it does not sell its therapies to other companies or directly to individuals at this time.
If its product candidates are successfully developed and approved, future 'customers' would likely include healthcare providers, hospitals, and potentially pharmacies, who would then administer or dispense the therapies to patients.
AI Analysis | Feedback
AI Analysis | Feedback
Randy Seidl
Chief Executive Officer and Director
Randy Seidl serves as the Chief Executive Officer and Director of Rain Oncology Inc..
Oanh Truong
Interim Chief Financial Officer
Oanh Truong is the Interim Chief Financial Officer of Rain Oncology Inc..
Robert C. Doebele M.D., Ph.D.
President, Chief Scientific Officer & Co-Founder
Dr. Robert C. Doebele is a Co-Founder, President, and Chief Scientific Officer of Rain Oncology Inc.. He co-founded Rain Therapeutics Inc. (now Rain Oncology Inc.) in April 2017. Dr. Doebele's expertise in precision oncology is central to shaping the company's corporate strategy and advancing its clinical pipeline and research and development efforts.
Richard P. Bryce MBChB, MFPM, MRCGP
Executive VP & Chief Medical Officer
Dr. Richard P. Bryce serves as the Executive Vice President and Chief Medical Officer. He joined Rain with over 30 years of experience in oncology, clinical research, and biopharmaceutical roles. Previously, he was Chief Medical and Scientific Officer at Puma Biotechnology, where he led the development of neratinib through FDA approval for breast cancer. His prior experience also includes senior medical director roles at Onyx Pharmaceuticals and various clinical and medical leadership positions at ICON Clinical Research, Ergomed Clinical Research, F. Hoffmann-La Roche, ILEX Oncology, Scotia Pharmaceuticals, and Servier Laboratories.
Vijaya Tirunagaru Ph.D.
Senior VP & Head of Research
Dr. Vijaya Tirunagaru is the Senior Vice President and Head of Research for Rain Oncology Inc.. She has contributed to the presentation of preclinical data for milademetan in MDM2-amplified tumors.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Rain Therapeutics Inc., a clinical-stage precision oncology company, focuses on developing therapies for various cancers. The addressable markets for its main products and services are detailed below:
Milademetan (MDM2 Inhibitor)
- Liposarcoma: Approximately 1,000 new cases of dedifferentiated liposarcoma (DDLPS) are estimated to occur in the U.S. annually. The global sarcoma drugs market, which includes liposarcoma, was valued at USD 2.1 billion in 2025 and is projected to reach USD 4.6 billion by 2035.
- Intimal Sarcoma: While specific market size data for intimal sarcoma is not readily available, it falls under the broader category of sarcomas. The global sarcoma drugs market was valued at USD 2.1 billion in 2025 and is predicted to reach USD 4.6 billion by 2035.
- Solid Tumors: Milademetan is also in Phase II clinical trials for solid tumors. Although there are currently no FDA-approved MDM2 inhibitors on the market, various MDM2 inhibitors are under investigation for their efficacy in solid tumors. The global protein inhibitors market, which may include MDM2 inhibitors, is estimated at USD 50 billion in 2025 and is projected to reach approximately USD 95 billion by 2033. The global cell cycle inhibitors market, which involves MDM2, was valued at USD 9.84 billion in 2024 and is projected to reach USD 21.71 billion by 2032.
RAD52 (DNA Repair Pathway Target)
- Global DNA Repair Drugs Market: The global DNA repair drugs market is projected to grow from USD 5.6 billion in 2024 to USD 10.7 billion by 2030.
- Breast Cancer: The global breast cancer therapeutics market was estimated at USD 31.5 billion in 2024 and is expected to grow to USD 71.3 billion by 2034. The U.S. breast cancer therapeutics market accounted for USD 11.9 billion in 2024.
- Ovarian Cancer: The global ovarian cancer drugs market size was valued at USD 3.5 billion in 2023 and is expected to reach USD 6.1 billion by 2032. The U.S. ovarian cancer drugs market size is estimated at USD 1.30 billion in 2025 and is projected to be around USD 2.57 billion by 2035.
- Pancreatic Cancer: The global pancreatic cancer treatment market was valued at USD 3 billion in 2023 and is anticipated to witness growth at a CAGR of 13.2% over the analysis period. Another estimate projects the global market size at USD 4.3 billion in 2026, reaching USD 12.6 billion by 2033, with North America expected to account for 38% of this market.
- Prostate Cancer: The global prostate cancer therapeutics market was valued at USD 12.6 billion in 2024 and is projected to reach USD 29.9 billion by 2034. North America accounted for 39.2% of the global market in 2024. The U.S. market was valued at USD 3.7 billion in 2021.
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- Rain Enhancement Technologies Holdco's shares outstanding were tracked from 2022 to 2025.
- As of March 13, 2026, the company had approximately 8.18 million total shares outstanding.
- As of September 30, 2025, Rain Enhancement Technologies Holdco had 8.19 million shares outstanding.
Capital Expenditures
- Rain Enhancement Technologies Holdco allocates capital towards developing, manufacturing, and commercializing its ionization rainfall generation technology.
- The focus of these expenditures includes improvements on existing rainfall generation technologies by introducing robust measurement tools, such as software monitoring technology, machine learning, rain gauges, and weather stations.
- A core area of investment is ionization-based cloud seeding technology to address global water scarcity.
Peer Outperformance in Environmental & Facilities Services
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Construction & Engineering | 29 | -8.2% | 92.7% | 152.3% | STRL 1265% · FIX 1201% · AGX 751% |
| Marine Transportation | 5 | 47.3% | 44.2% | 146.6% | MATX 183% · KEX 151% |
| Construction Machinery & Heavy Transportation Equipment | 13 | 16.0% | 61.2% | 102.0% | ALSN 260% · WAB 224% · CAT 221% |
| Aerospace & Defense | 52 | -12.4% | 62.8% | 70.6% | ATI 975% · FTAI 967% · HWM 604% |
| Trading Companies & Distributors | 19 | 20.9% | 40.4% | 58.3% | DXPE 413% · AIT 222% · URI 216% |
| Industrial Machinery & Supplies & Components | 72 | 6.2% | 55.1% | 36.5% | CRS 888% · MLI 337% · SYM 271% |
| Rail Transportation | 7 | 33.9% | 56.1% | 34.2% | CSX 55% · UNP 43% · NSC 34% |
| Diversified Support Services | 32 | 21.0% | 43.3% | 33.6% | CXW 240% · OPLN 169% · CACI 137% |
| Building Products | 32 | -6.2% | 13.0% | 24.0% | GFF 368% · TT 141% · JCI 118% |
| Cargo Ground Transportation | 16 | 33.6% | 10.8% | 9.9% | R 273% · XPO 263% · ARCB 27% |
| Electrical Components & Equipment | 37 | -6.2% | 74.9% | 5.4% | POWL 1808% · VRT 796% · BE 511% |
| Industrial Conglomerates | 17 | 14.6% | -0.6% | -5.4% | CSW 104% · CSL 81% · DD 67% |
| Office Services & Supplies | 9 | 25.6% | 20.4% | -11.2% | PBI 174% · TILE 165% · HNI 55% |
| Data Processing & Outsourced Services | 6 | -16.4% | 0.3% | -14.2% | EXLS 64% · BR 13% · G -13% |
| Research & Consulting Services | 13 | 4.9% | -10.7% | -19.3% | HURN 270% · FCN 31% · BAH 11% |
| Agricultural & Farm Machinery | 16 | 12.4% | -5.6% | -21.0% | DE 101% · TTC 22% · AGCO 6% |
| Security & Alarm Services | 9 | -54.3% | 16.3% | -27.6% | BCO 67% |
| Environmental & Facilities Services ← | 29 | -33.0% | 23.7% | -29.1% | GEO 228% · CLH 153% · RSG 95% |
| Passenger Airlines | 11 | 1.0% | 52.5% | -29.7% | LTM 2790% · UAL 128% · DAL 115% |
| Air Freight & Logistics | 12 | -24.7% | -8.8% | -39.0% | FDX 86% · EXPD 74% · CHRW 53% |
| Human Resource & Employment Services | 22 | 21.2% | -9.1% | -42.3% | ADP 48% · FA 28% · PAYX 9% |
| Passenger Ground Transportation | 3 | -18.8% | 39.7% | -63.3% | UBER 56% · LYFT -63% · CAR -67% |
| Airport Services | 4 | -53.4% | -61.7% | -86.5% | JOBY -51% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 82.45 |
| Mkt Cap | 10.6 |
| Rev LTM | 3,322 |
| Op Inc LTM | 558 |
| FCF LTM | 448 |
| FCF 3Y Avg | 448 |
| CFO LTM | 483 |
| CFO 3Y Avg | 468 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -3.9% |
| Rev Chg 3Y Avg | 7.5% |
| Rev Chg Q | -3.0% |
| QoQ Delta Rev Chg LTM | -0.4% |
| Op Inc Chg LTM | -1.3% |
| Op Inc Chg 3Y Avg | 15.1% |
| Op Mgn LTM | 13.9% |
| Op Mgn 3Y Avg | 14.0% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 12.9% |
| CFO/Rev 3Y Avg | 15.3% |
| FCF/Rev LTM | 10.5% |
| FCF/Rev 3Y Avg | 10.1% |
Segment Financials
Revenue by Segment| $ Mil | 2023 |
|---|---|
| Business of developing, manufacturing and commercializing ionization AEI technology | 0 |
| Total | 0 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Business of developing, manufacturing and commercializing ionization AEI technology | -8 | -5 |
| Total | -8 | -5 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Business of developing, manufacturing and commercializing ionization AEI technology | -9 | -5 |
| Total | -9 | -5 |
| $ Mil | 2023 |
|---|---|
| Business of developing, manufacturing and commercializing ionization AEI technology | 1 |
| Total | 1 |
Price Behavior
| Market Price | $0.54 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/23/2021 | |
| Distance from 52W High | -93.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.76 | $1.82 |
| DMA Trend | down | down |
| Distance from DMA | -28.6% | -70.2% |
| 3M | 1YR | |
| Volatility | 151.7% | 138.0% |
| Downside Capture | 271.97 | 305.97 |
| Upside Capture | -191.68 | -13.83 |
| Correlation (S&P 500) | 5.5% | 8.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.17 | 0.92 | -0.39 | 1.24 | 1.01 | -0.18 |
| Up Beta | -15.15 | -0.97 | -5.87 | 0.91 | -0.01 | -0.39 |
| Down Beta | 2.08 | 7.55 | 6.84 | 1.71 | 1.38 | 1.06 |
| Up Capture | -318% | -195% | -227% | -44% | -19% | -3% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 8 | 13 | 19 | 41 | 94 | 183 |
| Down Capture | 277% | 195% | 223% | 230% | 171% | 99% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 13 | 28 | 42 | 80 | 149 | 259 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | -90.7% | 138.0% | -1.08 | - |
| Sector ETF (XLI) | 10.7% | 17.3% | 0.42 | 2.6% |
| Equity (SPY) | 11.6% | 12.8% | 0.57 | 9.2% |
| Gold (GLD) | -2.3% | 28.6% | -0.09 | 4.9% |
| Commodities (DBC) | 43.1% | 20.9% | 1.60 | -6.3% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.50 | 6.4% |
| Bitcoin (BTCUSD) | -28.8% | 43.6% | -0.66 | 2.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | -41.7% | 135.0% | -0.49 | - |
| Sector ETF (XLI) | 11.7% | 17.6% | 0.50 | 4.4% |
| Equity (SPY) | 12.0% | 17.1% | 0.52 | 6.7% |
| Gold (GLD) | 16.5% | 19.0% | 0.69 | 4.7% |
| Commodities (DBC) | 8.4% | 19.6% | 0.31 | -3.4% |
| Real Estate (VNQ) | 1.1% | 18.9% | -0.05 | 6.4% |
| Bitcoin (BTCUSD) | 4.1% | 51.6% | 0.26 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | -23.7% | 135.0% | -0.49 | - |
| Sector ETF (XLI) | 13.4% | 20.1% | 0.58 | 4.4% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 6.7% |
| Gold (GLD) | 11.6% | 16.5% | 0.57 | 4.7% |
| Commodities (DBC) | 7.8% | 18.1% | 0.34 | -3.4% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 6.4% |
| Bitcoin (BTCUSD) | 61.7% | 66.3% | 1.01 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Insider Activity
Updated 8/20/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 8202026 | 0.95 | 110,000 | 104,225 | 715,205 | Form |
| 2 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 2.58 | 4,000 | 10,320 | 1,663,672 | Form |
| 3 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 2.53 | 30,000 | 75,900 | 1,621,310 | Form |
| 4 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 1.73 | 8,514 | 14,729 | 1,056,743 | Form |
| 5 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.78 | 4,787 | 27,669 | 59,228 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 8202026 | 0.95 | 110,000 | 104,225 | 715,205 | Form |
| 2 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 2.58 | 4,000 | 10,320 | 1,663,672 | Form |
| 3 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 2.53 | 30,000 | 75,900 | 1,621,310 | Form |
| 4 | Seidl, Randy | Chief Executive Officer | Direct | Buy | 5222026 | 1.73 | 8,514 | 14,729 | 1,056,743 | Form |
| 5 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.78 | 4,787 | 27,669 | 59,228 | Form | |
| 6 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.80 | 398 | 2,308 | 87,197 | Form | |
| 7 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.55 | 215 | 1,193 | 85,648 | Form | |
| 8 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.24 | 1,917 | 10,045 | 81,990 | Form |
Industry Resources
| Industrials Resources |
| IndustryWeek |
| Manufacturing.net |
| Aviation Week |
| Environmental & Facilities Services Resources |
| Waste360 |
| Waste Dive |
| FacilitiesNet |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.